Gastroenteropancreatic Neuroendocrine Tumors: Hormonal Treatment Updates
Gastroenteropancreatic neuroendocrine tumors are a heterogeneous group of carcinomas that remain difficult to treat with conventional cytotoxic regimens. The 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium brought us new insights into the management of gastroenteropancreatic neuroendocrine tumors. The focus of this review will serve to highlight specific Abstracts (#268 and #273) that help shed light on a novel, targeted means of treating gastroenteropancreatic neuroendocrine tumors.
Image: Carcinoid tumor of the small bowel (credit: Ed Uthman)
Khagi, S, Saif MW. Neuroendocrine Tumors: Treatment Updates. JOP. 2013 Jul 10;14(4):367-71 PMID 23846929
Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600 PMID 10080605
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656 PMID 19704057
R. Arnold, M. Wittenberg, A. Rinke, C. Schade-Brittinger, B. Aminossadati, E. Ronicke, T. M. Gress, H. H. Mueller, PROMID Study Group. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival. ASCO 2013 Abstract No: # 4030
E. M. Wolin, B. Jarzab, B. Eriksson, T. Walter, C. Toumpanakis, M. Morse, P. Tomassetti, M. Weber, D. R. Fogelman, J. Ramage, D. Poon, J. M. Huang, M. Hudson, X. Zhi, J. L. Pasieka, A. Mahamat, F. Swahn, J. Newell-Price, W. Mansoor, K. E. Oberg. A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs. ASCO 2013 Abstract No: # 4031
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D,Öberg. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514 PMID 21306238
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC, RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005 PMID 22119496
E. Bajetta, L. Catena, N. Fazio, S. Pusceddu, P. Biondani, G. Blanco, S. Ricci, M. Aieta, F. Pucci, M. Valente, N. Bianco, F. Bellomo, C. Mauri, P. Buonandi, V. Roberto. Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group. ASCO 2013 Abstract No: #4136
A. Vinik, E. M. Wolin, H. Audry, E. L. Gomez-Panzani. ELECT: A Phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs). 2014 GI Cancers Symposium Abstract No: #268
P.B. Ruszniewski, M. Caplin, J.W. Valle, C.L. Bohas, P. Maisonobe, P. Atlan. Patient-reported satisfaction with symptom control during lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients: Symnet, a large multinational, cross-sectional, observational study. 2014 GI Cancers Symposium Abstract No: #273
Copyright (c) 2014 Simon Khagi, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.